In response to the urgent concern plaguing the pharmaceutical industry, Eminence Business Media takes immense pride in announcing the highly anticipated Pharma Impurity Conclave 2023, a symposium dedicated to solving the stubborn challenges by complying with the esteemed pharma fraternity, on the 7th and 8th of September, in Hyderabad.
The paramount objective and recurring theme for the pharmaceutical sector shall forever be to uphold the safety and efficacy of medicinal compounds. In pursuit of these noble goals and in harmonious compliance with regulatory bodies, the global standards of the pharma industry have witnessed an unprecedented surge in R&D activities, fostering unparalleled quality benchmarks. The onus now lies on pharmaceutical professionals to shoulder the noble responsibility of delivering top-notch medications, transcending the boundaries of maladies and countries of focus.
While the exhaustive evolution of medicines has led to remarkable breakthroughs, the R&D journey has also encountered numerous challenges, particularly concerning drug impurities. With the advent of various discoveries and synthesis processes, various contaminants have been observed in drug formulations, presenting an array of complex challenges and disputes. However, driven by unwavering determination, the resolute pharma industry has confronted this diversity with remarkable efficiency and precision. Nevertheless, 2018 had a new obstacle in store – NITROSAMINES, which remains the most prominent concern for the industry.
Pharma Impurity Conclave 2023 aspires to surmount the most widely discussed challenges with unwavering efficacy, offering concrete solutions through in-depth exploration of the various layers of obstacles, thereby fortifying drug impurity profiling practices by evaluating their sources and processes. Though industry professionals are already familiar with multiple mechanisms of identification and risk assessment, the missing piece of the puzzle lies in quantifying uncertainty.
From delving into practical case studies to comprehending the latest guideline updates, this meticulously curated program is designed to address the most recent and pressing challenges concerning impurity mechanisms, adopting cutting-edge and distinctive learning tools. Attendees will have the unique opportunity to learn from distinguished experts and apply their theoretical hypotheses in the stimulating Pharma Impurity Conclave 2023 setting.
Thus, a new day brings forth another captivating program, wherein the timeless challenge is met with a fresh perspective and innovative approach, promising novel insights and solutions.
Fortis Technologies is a research-driven company founded on Research, Development and Manufacture of the latest HPLC and UHPLC columns. Established in 2005 to better meet the needs of the analyst in their chromatographic needs. Constant growth has seen the introduction of new products on a regular basis including first to market high PH silica columns and Mono-disperse particle HPLC columns. Technology is the key to our expertise, continuous investment in expanding our core strengths, silica matrix manufacture, surface coverage development, hardware design and column packing techniques lead to our performance being at the forefront of industry standards. Trends in the industries that we serve are always inbuilt to the products we design, ensuring that the products meet and indeed exceed the customer needs. Manufacture of silica is at the core of our business, producing the very latest surfaces to which we then add our innovative bonding chemistries. Full control of silica processes allows the ability to scale from UHPLC 1.7um Fortis technologies product range is available in India exclusively through Apex Chromatography Pvt. Ltd.
Shimadzu Corporation, Japan founded in 1875 and having a history of more than 140 years, is one of the leading Manufacturers suppliers of Analytical, scientific testing instruments such as Chromatography, Mass-Spectrometry, Spectroscopy, Testing instruments, Environmental monitoring instruments. Shimadzu Analytical (India) Pvt Ltd, a wholly owned subsidiary of Shimadzu Corporation, Japan, offers an extensive range of instruments, value added services customer support. Shimadzu has been serving the Indian scientific community since many decades now, through its well- established network of distributors namely Toshvin Analytical, Spinco Biotech, Swan Environmental Amkette Analytics for various product ranges. The Customer Support Centre (CSC) in India was established in 2006 to reaffirm the commitment towards our valued customers. It is a state-of-art facility with a wide range of analytical instruments and the key objective of providing application support continuous technical training for analytical scientists to offer the best possible solutions to face the challenges faced by the analysts.
Daicel Chiral Technologies (India) Pvt Ltd (DCTI) is an Indian subsidiary of Japan’s Daicel Corporation, specializing in Chiral Chromatography. DCTI was established in 2008 to support the pharmaceutical industry in the field of chiral chromatography. Further, DCTI has emerged as a leader in Pharma Services (Analytical, Purification, Synthesis) and Pharma Standards (Impurities, Peptides, Labeled). GMP Analytical Services Division had successful US-FDA inspections and maintaining Zero 483 consistency. DCTI solutions encompass AMD / AMV, Extractable & Leachable Studies, IVBE studies, and Peptide
Analytics, Impurity isolation / Characterization studies, custom synthesis of stable isotope labeled standards and impurity standards spanning small molecules to complex Peptides.